Pharsight

Ovide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7560445 TARO PHARM INDS LTD Process for preparing malathion for pharmaceutical use
Feb, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977324 TARO PHARM INDS LTD Process for preparing malathion for pharmaceutical use
Aug, 2026

(2 years from now)

Ovide is owned by Taro Pharm Inds Ltd.

Ovide contains Malathion.

Ovide has a total of 2 drug patents out of which 0 drug patents have expired.

Ovide was authorised for market use on 02 August, 1982.

Ovide is available in lotion;topical dosage forms.

Ovide can be used as treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair.

The generics of Ovide are possible to be released after 01 February, 2027.

Drugs and Companies using MALATHION ingredient

Market Authorisation Date: 02 August, 1982

Treatment: Treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair

Dosage: LOTION;TOPICAL

How can I launch a generic of OVIDE before it's drug patent expiration?
More Information on Dosage

OVIDE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic